Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352423 | 0.88 | CA1 (0.38) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL29358193 | 0.88 | CA1 (0.38) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL29639554 | 0.87 | CA1 (0.38) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL19469294 | 0.85 | CA1 (0.36) | CA1CA2CA7CA9 | |
| SCHEMBL29355132 | 0.80 | POLB (0.36) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL12929986 | 0.80 | POLB (0.36) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL28513987 | 0.79 | ALDH1A1 (0.34) | CA1CA2CA7CA9FABP3 | |
| SCHEMBL30966657 | 0.79 | POLB (0.35) | CA1CA2CA7CA9POLB | |
| SCHEMBL28859005 | 0.79 | POLB (0.35) | CA1CA2CA7CA9POLB | |
| SCHEMBL17544900 | 0.78 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360141-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-11-27 | — | — | US | disclosed |
| US-12433897-B2 | Pyridine derivatives with n-linked cyclic substituents as cGAS inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-10-07 | — | — | US | disclosed |
| US-20240342186-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-10-17 | — | — | US | disclosed |
| US-20230000878-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342186-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | CGAS, GLS2, GMPS | CA1 3592/4885CA2 3653/4885CA7 2394/4885 |
| US-20250360141-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | CGAS, GLS2, GMPS | CA1 3535/4885CA2 3571/4885CA7 2280/4885 |
| US-20230000878-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | CGAS, GLS2, GMPS | CA1 3592/4885CA2 3653/4885CA7 2394/4885 |
| US-12433897-B2 | Pyridine derivatives with n-linked cyclic substituents as cGAS inhibitors | CGAS, GLS2, GMPS | CA1 3592/4885CA2 3653/4885CA7 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.